esmo – Page 3 – pharmaceutical daily

September 28, 2019 Off

Opdivo superior recurrence-free survival (RFS) compared to Yervoy in resected high-risk melanoma patients

Bristol Myers Squib’s adjuvant treatment with Opdivo (nivolumab) further showed extended recurrence-free survival at three years in resected high-risk melanoma patients, being the longest follow-up of any PD-1 inhibitor in the adjuvant melanoma setting.

October 11, 2016 Off

ESMO 2016: Single-Arm Trials Improve Early Access to Rare Cancer Drugs

By Dino Mustafić

Although randomised clinical trials (RCTs) remain the gold standard for evaluating the benefit/risk of cancer drugs, single-arm trials (SATs) can provide invaluable opportunities to speed up cancer drug development and approval, in particular for drugs with dramatic activity and strong biological rationale in small populations with high unmet need, Dr. Jorge Martinalbo, Scientific Officer at the European Medicines Agency (EMA) reported at the ESMO 2016 Congress.